Login / Signup

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.

Noffar BarJoris DielsSuzy van SandenJoão MendesTeresa HernandoHeather BurnettPatricia CostJordan M SchecterNikoletta LendvaiNitin PatelTadao IshidaJeremy ErSimon J HarrisonNieves Lopez-Muñoz
Published in: Current medical research and opinion (2024)
For patients with triple-class exposed RRMM treated with 2-4 prior lines of treatment, cilta-cel was found to provide superior clinical benefit over ide-cel in terms of response and progression-free survival.
Keyphrases
  • multiple myeloma
  • free survival
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • mesenchymal stem cells
  • newly diagnosed
  • smoking cessation